Open AccessAssessment of the control measures for category A diseases of Animal Health Law: Contagious Caprine Pleuropneumonia
Author(s) -
Nielsen Søren Saxmose,
Alvarez Julio,
Bicout Dominique Joseph,
Calistri Paolo,
Canali Elisabetta,
Drewe Julian Ashley,
GarinBastuji Bruno,
Gonzales Rojas José Luis,
Gortázar Christian,
Herskin Mette,
Michel Virginie,
Miranda Chueca Miguel Ángel,
Padalino Barbara,
Pasquali Paolo,
Spoolder Hans,
Ståhl Karl,
Velarde Antonio,
Viltrop Arvo,
Winckler Christoph,
Gubbins Simon,
Stegeman Jan Arend,
Thiaucourt François,
Antoniou SotiriaEleni,
Aznar Inma,
Papanikolaou Alexandra,
Zancanaro Gabriele,
Roberts Helen Clare
Publication year - 2022
Publication title -
efsa journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.076
H-Index - 97
ISSN - 1831-4732
DOI - 10.2903/j.efsa.2022.7068
Subject(s) - medicine , european commission , mandate , environmental health , expert opinion , veterinary medicine , european union , law , business , political science , intensive care medicine , economic policy
EFSA received a mandate from the European Commission to assess the effectiveness of some of the control measures against diseases included in the Category A list according to Regulation (EU) 2016/429 on transmissible animal diseases (‘Animal Health Law’). This opinion belongs to a series of opinions where these control measures will be assessed, with this opinion covering the assessment of control measures for Contagious Caprine Pleuropneumonia (CCPP). In this opinion, EFSA and the AHAW Panel of experts review the effectiveness of: (i) clinical and laboratory sampling procedures, (ii) monitoring period, (iii) the minimum radius of the protection and surveillance zones and iv) the minimum length of time the measures should be applied in these zones. The general methodology used for this series of opinions has been published elsewhere. Several scenarios for which these control measures had to be assessed were designed and agreed prior to the start of the assessment. Different clinical and laboratory sampling procedures are proposed depending on the scenarios considered. The monitoring period of 45 days was assessed as effective in affected areas where high awareness is expected, and when the index case occurs in an area where the awareness is low the monitoring period should be at least 180 days (6 months). Since transmission kernels do not exist and data to estimate transmission kernels are not available, a surveillance zone of 3 km was considered effective based on expert knowledge, while a protection zone should also be developed to include establishments adjacent to affected ones. Recommendations, provided for each of the scenarios assessed, aim to support the European Commission in the drafting of further pieces of legislation, as well as for plausible ad hoc requests in relation to CCPP.